Oncolix, Inc. announced on October 4, 2017, the Board of Directors voted to increase the number of directors to three from the current two and elected Jerry R. Youkey, and Dale Zajicek to serve on the company's Board of Directors. Mr. Zajicek is the first independent board member of the company. Dr. Youkey and Mr. Zajicek have served as directors of the company's wholly owned subsidiary, Oncolix, Inc. In connection with such action, J. Donald Payne resigned as a director of the company but continues to serve as its secretary. Michael T. Redman, chief executive officer of thje company, continues to serve as the company's third director. The term of all directors continues until their reelection or replacement by action of the stockholders of the company. Jerry R. Youkey currently serves as GHS Executive Vice President and Chief Academic Officer, reporting to the CEO. Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotechnology industry.